A number of research firms have changed their ratings and price targets for Prima BioMed (NASDAQ: PBMD):

  • 9/20/2016 – Prima BioMed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
  • 9/13/2016 – Prima BioMed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
  • 9/8/2016 – Prima BioMed was given a new $6.00 price target on by analysts at FBR & Co. They now have a “buy” rating on the stock.
  • 9/7/2016 – Prima BioMed was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
  • 9/1/2016 – Prima BioMed was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “
  • 8/26/2016 – Prima BioMed had its “buy” rating reaffirmed by analysts at Roth Capital. They now have a $6.00 price target on the stock.
  • 8/26/2016 – Prima BioMed had its “buy” rating reaffirmed by analysts at FBR & Co. They wrote, “We expect the stock to stabilize and resume edging higher; we reiterate our Buy rating and $91 PT.””
  • 8/17/2016 – Prima BioMed was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Prima Biomed Ltd is a biotechnology company focused on developing oncology therapies in the field of immunotherapy. The Company’s key product candidates in development include CVac, an autologous dendritic cell vaccine for ovarian cancer, monoclonal antibodies for multiple tumor types, and an oral formulation for the Human Papilloma Virus. Prima Biomed Ltd is based in Sydney, Australia. “

Prima BioMed Ltd. (NASDAQ:PBMD) opened at 0.88 on Wednesday. Prima BioMed Ltd. has a one year low of $0.72 and a one year high of $1.54. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $0.95. The firm’s market cap is $60.47 million.

Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company’s main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response.

5 Day Chart for NASDAQ:PBMD

Receive News & Ratings for Prima BioMed Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prima BioMed Ltd and related companies with MarketBeat.com's FREE daily email newsletter.